KR890005103A - 노인성 치매의 치료에 유용한 티아디아졸 - Google Patents
노인성 치매의 치료에 유용한 티아디아졸 Download PDFInfo
- Publication number
- KR890005103A KR890005103A KR1019880011706A KR880011706A KR890005103A KR 890005103 A KR890005103 A KR 890005103A KR 1019880011706 A KR1019880011706 A KR 1019880011706A KR 880011706 A KR880011706 A KR 880011706A KR 890005103 A KR890005103 A KR 890005103A
- Authority
- KR
- South Korea
- Prior art keywords
- thiadiazol
- methyl
- azabicyclo
- tetrahydropyridine
- quinuclidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Cephalosporin Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 환 탄소원자중 하나의 환 탄소 상에서 비-방향족 아자사이클릭 또는 아자비사이클릭 환 시스템으로 치환되고, 다른 환 탄소 상에서 친유성이 낮은 치환체 또는 탄화수소 치환체로 치환됨을 특징으로 하는 티아디아졸, 또는 이의 염 또는 프로드럭(prodrug).
- 제1항에 있어서, 하기 일반식(II)의 화합물, 또는 이의 염 또는 프로드럭.(Ⅱ)상기식에서, R1은 비-방향족 아자사이클릭 또는 아자비사이클릭 환 시스템이고; R2는 수소, 할로겐, -CF3, -OR7, -SR7, -NR7R8, -NHOR7, -NHNH2, -CN, -CO2R7, 또는 -CINR7R8(여기에서, R7및 R8은 독립적으로 수소 또는 C1-2알킬이다), 또는 치환되거나 비치환되고, 포화되거나 불포화된 탄화수소 그룹이다.
- 제1항 또는 제2항에 있어서, 아자사이클릭 또는 아자비사이클릭 환 시스템이 C1-3알킬 또는 하이드록시로 임의 치환될 수 있는 피롤리딘, 퀴누클리딘, 테트라하이드로피리딘, 피페리딘, 데하이드로트로판, 피롤리지딘, 아자노르보난 또는 이소퀴누클리딘인 화합물.
- 제2항 또는 제3항에 있어서, R2가 수소, C1-6알킬, C2-6사이클로알킬, 아미노 또는 디메틸아미노인 화합물.
- 제2항 또는 제3항에 있어서, R2가 구조식의 그룹인 화합물.
- 3-[5-(3-메틸-1,2,4-티아디아졸)-일]피롤리딘; 1-메틸-3-[5-(3-메틸-1,2,4-티아디아졸)-일]-피롤리딘; 3-[5-(3-메틸-1,2,4-티아디아졸)-일]퀴누클리딘; 3-[5-(3-메틸-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-페닐-1,2,4-티아디아졸)-일]퀴누클리딘; 3-[5-(1,2,4-티아디아졸)-일]퀴누클리딘; 3-[5-(3-디메틸아미노-1,2,4-티아디아졸)-일]-퀴누클리딘; 3-[5-(3-메틸머캅토-1,2,4-티아디아졸)-일]퀴누클리딘; 3-[5-(3-에틸-1,2,4-티아디아졸)-일]-퀴누클리딘; 3-[5-(3-사이클로프로필-1,2,4-티아디아졸)-일]-퀴누클리딘; 3-[5-(3-디메틸아미노-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-메톡시-1,2,4-티아디아졸)-일]-퀴누클리딘; 5-[5-(1,2,4-티아디아졸)-일]-아자비사이클로[2.2.1]헵탄; 3-[5-(3-사이클로프로필-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-벤질-1,2,4-티아디아졸)-일]-퀴누클리딘; 3-[5-(3-3급-부틸-1,2,4-티아디아졸)-일]-퀴누클리딘; 5-[5-(3-메틸-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄-3-올; 3-[5-(3-이소프로필-1,2,4-티아디아졸)-일]-퀴누클리딘; 3-[5-(3-에틸-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 1-메틸-3-[5-(1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 1-메틸-3-[5-(3-메틸-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-메틸-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-(1-하이드록시-1-페닐메틸)-1,2,4-티아디아졸)-일]퀴누클리딘; 3-[5-(3-벤조일-1,2,4-티아디아졸)-일]퀴누클리딘; 3-[5-(3-(1,1-디페닐-1-하이드록시메틸)-1,2,4-티아디아졸)-일]퀴누클리딘; 6-[5-(3-메틸-1,2,4-티아디아졸)-일]-1-아자비사이클로[3.2.1]옥탄; 1-메틸-3-[5-(3-디메틸아미노-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-디메틸아미노-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 1-메틸-3-[5-(3-메틸아미노-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 1-메틸-3-[5-(3-에틸아미노-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 5-[5-(3-디메틸아미노-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄-3-올; 3-[5-(3-이소프로필-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 6-[5-(3-사이클로프로필-1,2,4-티아디아졸)-일]-2-아자비사이클로[2.2.2.]옥탄; 3-[5-(3-n-프로필-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-메톡시-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-메틸티오-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-n-프로필-1,2,4-티아디아졸)-일]퀴누클리딘; 6-[5-(3-이소프로필-1,2,4-티아디아졸)-일]-2-아자비사이클로[2.2.2]옥탄; 6-[5-(3-에틸-1,2,4-티아디아졸)-일]-2-아자비사이클로[2.2.2]옥탄; 5-[5-(3-이소프로필-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄-3-올; 3-[5-(3-벤질-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 1-메틸-3-[5-(3-아미노-1,2,4-티아디아졸)-일]-피롤리딘; 1-메틸-3-[5-(3-아미노-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-아미노-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-아미노-1,2,4-티아디아졸)-일]퀴누클리딘; 6-[5-(3-메틸-1,2,4-티아디아졸)-일]-1-아자비사이클로[3.2.1]옥탄; 6-[5-(3-아미노-1,2,4-티아디아졸)-일]-1-아자비사이클로[3.2.1]옥탄; 3-[5-(3-아미노-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 5-[5-(3-메틸-1,2,4-티아디아졸)-일]퀴누클리딘-3-올; 5-[5-(3-아미노-1,2,4-티아디아졸)-일]퀴누클리딘-3-올; 5-메틸-3-[5-(3-메틸-1,2,4-티아디아졸)-일]-퀴누클리딘; 5-메틸-3-[5-(3-아미노-1,2,4-티아디아졸)-일]-퀴누클리딘; 5-[5-(3-아미노-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄-3-올; 5-메틸-3-[5-(3-메틸-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 5-메틸-3-[5-(3-아미노-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-에톡시-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-클로로-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-메틸아미노-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-에틸아미노-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄; 3-[5-(3-에틸-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-n-프로필-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-사이클로프로필-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-벤질-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-메틸아미노-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-에틸아미노-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 1-메틸-3-[5-(3-에틸-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 1-메틸-3-[5-(3-사이클로프로필-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 1-메틸-3-[5-(3-벤질-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 1-메틸-3-[5-(3-메톡시-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 1-메틸-3-[5-(3-메틸티오-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 1-메틸-3-[5-(3-이소프로필-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 3-[5-(3-이소프로필-1,2,4-티아디아졸)-일]-1,2,5,6-테트라하이드로피리딘; 5-[5-(3-사이클로프로필-1,2,4-티아디아졸)-일]-1-아자비사이클로[2.2.1]헵탄-3-올; 및 6-[5-(3-디메틸아미노-1,2,4-티아디아졸)-일]-2-아자비사이클로[2.2.2]옥탄 중에서 선택되는 화합물, 이의 염 및 프로드럭.
- 제1항 내지 제6항중 어느 한 항에서 청구한 화합물을 약제학적으로 허용되는 담체와 함께 함유함을 특징으로 하는 약제학적 조성물.
- 제7항에 있어서, 추가로 말초 콜린성 길항 물질을 함유함을 특징으로 하는 약제학적 조성물.
- 신경성 및 정신성 질환 및/또는 극심한 통증 상태를 치료하기 위한 약제를 제조하기 위한 제1항 내지 제6항중 어느 한 항에서 청구한 화합물의 용도.
- (A) 하기 일반식(III)의 화합물을 폐환시키거나; (B) 하기 일반식(V)의 니트릴 설파이드를 하기 일반식(VI)의 니트릴로 고리화 첨가 반응시키거나; (C) 하기 일반식(IV)의 티아디아졸을 음이온 -Ra를 제공하는 시약과 반응시키거나; (D) 하기 일반식(VII)의 디아민을 염화황과 반응시키거나; 또는 (E) 하기 일반식(VIII)의 티오세미카바자이드를 탈수시킴을 특징으로 하여, 제1항 내지 제6항중 어느 한 항에서 청구한 화합물을 제조하는 방법(Ⅲ)(Ⅳ)Ra-C≡N+-S-(Ⅴ)RbCN (Ⅵ)(Ⅶ)RXCSNHNHCONRPRg(Ⅷ)상기식에서, Ra및 Rb중의 하나는 제2항에서 정의된 R1이고, 다른 하나는 제2항에서 정의된 R2이며; Rc는 수소 또는 알킬 그룹이고; X는 할로겐이며; Rx는 아자사이클릭 또는 아자비사이클릭 환 시스템이고; Rp및 Rq는 수소 또는 알킬 그룹이다.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB?8801758? | 1987-01-27 | ||
GB878721342A GB8721342D0 (en) | 1987-09-10 | 1987-09-10 | Therapeutic agents |
GB?8721342? | 1987-09-10 | ||
GB888801758A GB8801758D0 (en) | 1988-01-27 | 1988-01-27 | Therapeutic agents |
GB888812145A GB8812145D0 (en) | 1988-05-23 | 1988-05-23 | Therapeutic agents |
GB?8812145.4? | 1988-05-23 | ||
GB888817311A GB8817311D0 (en) | 1988-07-20 | 1988-07-20 | Therapeutic agents |
GB?8817311.7? | 1988-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR890005103A true KR890005103A (ko) | 1989-05-11 |
Family
ID=27449981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019880011706A KR890005103A (ko) | 1987-01-27 | 1988-09-10 | 노인성 치매의 치료에 유용한 티아디아졸 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0307142B1 (ko) |
JP (1) | JPH01104070A (ko) |
KR (1) | KR890005103A (ko) |
AT (1) | ATE111464T1 (ko) |
AU (1) | AU626209B2 (ko) |
DE (1) | DE3851498T2 (ko) |
DK (1) | DK503188A (ko) |
IL (1) | IL87643A (ko) |
NZ (1) | NZ225999A (ko) |
PT (1) | PT88422B (ko) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE133415T1 (de) * | 1987-04-15 | 1996-02-15 | Beecham Group Plc | Am brückenkopf substituierte azabicyclenderivate |
CA2000041A1 (en) * | 1988-10-13 | 1990-04-13 | Barry S. Orlek | Compounds |
GB8830226D0 (en) * | 1988-12-23 | 1989-02-22 | Beecham Group Plc | Novel compounds |
US5260311A (en) * | 1989-02-22 | 1993-11-09 | Novo Nordisk A/S | Piperidine compounds and their use |
US5328925A (en) * | 1989-02-22 | 1994-07-12 | Novo Nordisk A/S | Piperidine compounds and their use |
US5264444A (en) * | 1989-02-22 | 1993-11-23 | Novo Nordisk A/S | Piperidine compounds and use |
US5043345A (en) * | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
US5106853A (en) * | 1989-05-15 | 1992-04-21 | Merck Sharp & Dohme, Ltd. | Oxadiazole and its salts, their use in treating dementia |
EP0413545B1 (en) * | 1989-08-16 | 1997-05-14 | Beecham Group Plc | Azabicyclic compounds |
DE69026197T2 (de) * | 1989-10-07 | 1997-01-09 | Beecham Group Plc | Azabizyklische Verbindungen, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
EP0459568A3 (en) * | 1990-05-31 | 1992-09-30 | Merck Sharp & Dohme Ltd. | Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use |
US5418240A (en) * | 1990-08-21 | 1995-05-23 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
US5376668A (en) * | 1990-08-21 | 1994-12-27 | Novo Nordisk A/S | Heterocyclic compounds |
DK198390D0 (da) | 1990-08-21 | 1990-08-21 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
DK198590D0 (da) * | 1990-08-21 | 1990-08-21 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
US5527813A (en) * | 1990-08-21 | 1996-06-18 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
DK198490D0 (da) * | 1990-08-21 | 1990-08-21 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
US5124460A (en) * | 1991-05-06 | 1992-06-23 | Merck Sharp & Dohme Ltd. | Enantioselective synthesis of 3-substituted 1-azabicyclo (2.2.1)heptanes |
US5641791A (en) * | 1991-08-13 | 1997-06-24 | Novo Nordisk A.S | Heterocyclic compounds and their preparation and use |
GB9127279D0 (en) * | 1991-12-23 | 1992-02-19 | Ici Plc | Heterocyclic derivatives |
WO1993014089A1 (en) * | 1992-01-13 | 1993-07-22 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
WO1993021184A1 (en) * | 1992-04-10 | 1993-10-28 | Zeneca Limited | Biphenylylquinuclidine derivatives as squalene synthase inhibitors |
SE9201478D0 (sv) * | 1992-05-11 | 1992-05-11 | Kabi Pharmacia Ab | Heteroaromatic quinuclidinenes, their use and preparation |
GB9211796D0 (en) * | 1992-06-04 | 1992-07-15 | Ici Plc | Heterocyclic derivatives |
GB9216721D0 (en) * | 1992-08-06 | 1992-09-23 | Ici Plc | Therapeutic heterocyclic derivatives |
GB9218334D0 (en) * | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
JPH08504801A (ja) * | 1992-12-21 | 1996-05-28 | ゼネカ・リミテッド | スクアレンシンターゼ阻害剤としてのキヌクリジン誘導体 |
GB9226573D0 (en) * | 1992-12-21 | 1993-02-17 | Ici Plc | Heterocyclic compounds |
US5753683A (en) * | 1993-08-19 | 1998-05-19 | Novo Nordisk A/S | Antipsychotic method |
US6281232B1 (en) | 1993-08-19 | 2001-08-28 | Novo Nordisk A/S | Method of treating gastrointestinal motility disorders |
CZ285030B6 (cs) * | 1993-08-19 | 1999-05-12 | Novo Nordisk A/S | Použití thiadiazolových a oxadiazolových sloučenin pro výrobu farmaceutického prostředku a farmacetický prostředek pro léčení schizofrenie nebo schizofrenních nemocí |
US6265419B1 (en) | 1993-12-21 | 2001-07-24 | Novo Nordisk A/S | Method of treating gastrointestinal motility disorders |
IL112024A (en) * | 1993-12-21 | 1999-07-14 | Novo Nordisk As | Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders |
US5545638A (en) * | 1993-12-21 | 1996-08-13 | Novo Nordisk A/S | Method of treating gastrointestinal motility disorders |
US5672709A (en) * | 1994-10-24 | 1997-09-30 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
US5565475A (en) * | 1994-11-08 | 1996-10-15 | Muhlhauser; Mark A. | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives |
US5612351A (en) * | 1994-11-08 | 1997-03-18 | Novo Nordisk A/S | Method of treating urinary bladder dysfunctions |
US5510478A (en) * | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
EP0809494A1 (en) * | 1995-02-17 | 1997-12-03 | Novo Nordisk A/S | The use of heterocyclic compounds |
GB9510459D0 (en) | 1995-05-24 | 1995-07-19 | Zeneca Ltd | Bicyclic amines |
US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
JP2000501097A (ja) * | 1995-11-29 | 2000-02-02 | イーライ・リリー・アンド・カンパニー | ヘテロ環式化合物およびそれらの使用 |
US5889019A (en) * | 1995-11-29 | 1999-03-30 | Eli Lilly And Company | Heterocyclic compounds and their use |
IL124419A0 (en) * | 1995-12-07 | 1998-12-06 | Lilly Co Eli | Composition for treating pain |
US5914338A (en) * | 1996-04-02 | 1999-06-22 | Novo Nordisk | Heterocyclic compounds and their preparation and use |
ATE250055T1 (de) * | 1996-04-24 | 2003-10-15 | Novo Nordisk As | Heterozyklische verbindungen, ihre herstellung und ihre anwendung |
AU722015B2 (en) * | 1996-05-13 | 2000-07-20 | Zeneca Limited | Bicyclic amines |
US6117890A (en) * | 1996-08-01 | 2000-09-12 | Eli Lilly And Company | Method for treating bipolar disorder |
EP0821956A1 (en) * | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating disruptive behavior disorders |
US6090829A (en) * | 1996-08-01 | 2000-07-18 | Eli Lilly And Company | Method for treating excessive aggression |
US6043258A (en) * | 1996-08-01 | 2000-03-28 | Eli Lilly And Company | Method for treating disruptive behavior disorders with xanomeline |
EP0821954A1 (en) * | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating mental retardation |
US5834458A (en) * | 1996-10-09 | 1998-11-10 | Eli Lilly And Company | Heterocyclic compounds and their use |
GB9623944D0 (en) * | 1996-11-15 | 1997-01-08 | Zeneca Ltd | Bicyclic amine derivatives |
GB9624114D0 (en) * | 1996-11-20 | 1997-01-08 | Zeneca Ltd | Pesticidal bicyclic amine derivatives |
HUP0000582A3 (en) | 1996-11-26 | 2001-10-29 | Zeneca Ltd | Insecticidal, acaricidal and nematocidal 8-azabicyclo[3.2.1]octane-, 8-azabicyclo[3.2.1]oct-6-ene-, 9-azabicyclo[3.3.1]nonane-, 9-aza-3-oxabicyclo[3.3.1]nonane- and 9-aza-3-thiabicyclo[3.3.1]nonane derivatives, preparation and use thereof |
GB9624611D0 (en) * | 1996-11-26 | 1997-01-15 | Zeneca Ltd | Bicyclic amine compounds |
US5733912A (en) * | 1997-02-19 | 1998-03-31 | Abbott Laboratories | 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission |
US6034108A (en) * | 1997-07-28 | 2000-03-07 | Eli Lilly And Company | Method for treating mental retardation |
US7332508B2 (en) * | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
US8022223B2 (en) | 2006-03-24 | 2011-09-20 | Array Biopharma, Inc. | 2-aminopyridine analogs as glucokinase activators |
UY30916A1 (es) * | 2007-02-15 | 2008-09-30 | Argenta Discovery Ltd | Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros |
JP2008270387A (ja) * | 2007-04-18 | 2008-11-06 | Matsushita Electric Ind Co Ltd | プリント配線板 |
EP2072506A1 (de) * | 2007-12-21 | 2009-06-24 | Bayer CropScience AG | Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide |
JP2011520905A (ja) | 2008-05-15 | 2011-07-21 | ザ・ユニバーシティ・オブ・トレド | 向知性剤としてのムスカリンアゴニスト |
US9549928B2 (en) | 2011-04-29 | 2017-01-24 | The University Of Toledo | Muscarinic agonists as enhancers of cognitive flexibility |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3770749A (en) * | 1971-07-01 | 1973-11-06 | Monsanto Co | 3-pyridyl-1,2,4-thiadiazole-5-carboxamides |
BE789441A (fr) * | 1971-09-30 | 1973-03-29 | Ciba Geigy | Nouvel herbicide selectif et procede pour sa preparation |
US4226609A (en) * | 1979-03-01 | 1980-10-07 | Olin Corporation | Selected 3-trichloromethyl-5-cyclic amine-1,2,4-thiadiazole compounds and their use as ammonium nitrification inhibitors |
EP0018497B1 (de) * | 1979-04-06 | 1982-04-28 | Bayer Ag | Azolyloxy-essigsäureamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide |
US4282144A (en) * | 1979-06-01 | 1981-08-04 | Eastman Kodak Company | Azo dyes derived from 5-membered heterocyclic amines and aromatic amine couplers containing sulfo groups, or salts thereof |
US4301069A (en) * | 1980-06-13 | 1981-11-17 | Eastman Kodak Company | Azo dyes from five membered ring heterocyclic amines and aniline, tetrahydroquinoline and benzomorpholine couplers containing thiosulfate alkyl groups |
DE3038636A1 (de) * | 1980-10-13 | 1982-05-27 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von substituierten oxyessigsaeureamiden |
DE3422861A1 (de) * | 1984-06-20 | 1986-01-02 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von heteroaryloxyacetamiden |
NZ219646A (en) * | 1986-03-27 | 1990-10-26 | Merck Sharp & Dohme | Oxadiazole derivatives of azacyclics for treating cns disorders |
DE3789039T2 (de) * | 1986-06-27 | 1994-06-09 | Beecham Group Plc | Verbrückte bicyclische N-heterocyclische Verbindungen. |
NZ227841A (en) * | 1988-02-12 | 1991-08-27 | Merck Sharp & Dohme | Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions |
JP3353406B2 (ja) * | 1993-08-16 | 2002-12-03 | 富士電機株式会社 | 燃料電池発電装置 |
-
1988
- 1988-08-31 NZ NZ225999A patent/NZ225999A/en unknown
- 1988-09-01 DE DE3851498T patent/DE3851498T2/de not_active Revoked
- 1988-09-01 IL IL8764388A patent/IL87643A/en not_active IP Right Cessation
- 1988-09-01 AT AT88308127T patent/ATE111464T1/de not_active IP Right Cessation
- 1988-09-01 EP EP88308127A patent/EP0307142B1/en not_active Revoked
- 1988-09-05 PT PT88422A patent/PT88422B/pt not_active IP Right Cessation
- 1988-09-09 DK DK503188A patent/DK503188A/da not_active Application Discontinuation
- 1988-09-09 AU AU22073/88A patent/AU626209B2/en not_active Ceased
- 1988-09-10 KR KR1019880011706A patent/KR890005103A/ko not_active Application Discontinuation
- 1988-09-10 JP JP63225567A patent/JPH01104070A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PT88422B (pt) | 1992-10-30 |
EP0307142A1 (en) | 1989-03-15 |
NZ225999A (en) | 1992-04-28 |
DK503188A (da) | 1989-05-01 |
AU626209B2 (en) | 1992-07-23 |
PT88422A (pt) | 1989-07-31 |
JPH01104070A (ja) | 1989-04-21 |
DE3851498T2 (de) | 1995-05-04 |
DE3851498D1 (de) | 1994-10-20 |
DK503188D0 (da) | 1988-09-09 |
IL87643A0 (en) | 1989-02-28 |
IL87643A (en) | 1994-05-30 |
ATE111464T1 (de) | 1994-09-15 |
EP0307142B1 (en) | 1994-09-14 |
AU2207388A (en) | 1989-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890005103A (ko) | 노인성 치매의 치료에 유용한 티아디아졸 | |
KR890002132A (ko) | 옥사디아졸 무스카린성 효능제 프로드럭 | |
US5260314A (en) | Certain 3-(1,2,5-oxa- or thiadiazol-4-yl)-1-azabicyclo [2.2.2]octanes having pharmaceutical properties | |
US5418240A (en) | Heterocyclic compounds and their preparation and use | |
KR890013011A (ko) | 결합된 아자사이클릭 환 치환체를 갖는 5-원 환 시스템 | |
KR880001291A (ko) | 세로토닌 길항물질의 치료학적 사용방법 | |
EP0628041B1 (en) | Heterocyclic compounds and their preparation and use | |
KR870008883A (ko) | 노인성 치매의 치료에 유용한 옥사디아졸 및 그의 제조 방법 | |
US5134146A (en) | Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma | |
EP0366304B1 (en) | Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | |
GB8808433D0 (en) | Therapeutic agents | |
WO1991009593A2 (en) | 5-ht3 antagonists for treatment of nausea, bradycardia of hypotension associated with myocardial instability | |
US5405853A (en) | Thiadiazoles useful in the treatment of senile dementia | |
KR910004616A (ko) | 신규 화합물 | |
US6117883A (en) | Heterocyclic compounds | |
KR910004608A (ko) | 신규 화합물 | |
AU660609B2 (en) | Azacyclic or azabicyclic compounds, their preparation and use | |
GB1010231A (en) | Substituted 3-phenyl-5-imino-4,5 dihydro-1,2,4-oxadiazoles, process for their manufacture and therapeutic compositions containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |